ADVB Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
127.6K
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
127.6K
0
0
0
0
Operating Expenses
5.0M
+871.4%
519.8K
+31.1%
396.6K
-24.3%
523.9K
+4527.8%
11.3K
R&D
-665140
-373.5%
243.2K
+30.5%
186.3K
-21.0%
236.0K
+139.3%
-600056
SG&A
5.7M
+1966.1%
276.6K
+31.5%
210.3K
-27.0%
287.9K
-52.9%
611.4K
Operating Income
-4922189
-846.9%
-519836
-31.1%
-396642
+24.3%
-523914
-4527.8%
-11321
EBITDA
-4966650
-872.9%
-510510
-24.7%
-409499
+14.0%
-475922
-500.3%
-79286
Net Income
695.0K
+242.1%
-488942
-107.1%
6.9M
+1872.5%
-386901
+44.9%
-701611
EPS (Basic)
—
$-0.38
-106.1%
$6.20
+1650.0%
$-0.40
-17.6%
$-0.34
EPS (Diluted)
—
$-0.38
-106.1%
$6.20
+1650.0%
$-0.40
-17.6%
$-0.34
Shares (Diluted)
—
1.3M
+18.8%
1.1M
+0.0%
1.1M
-47.3%
2.1M
Advanced Biomed (ADVB) — Financials